Gamma delta T cells occupy a curious middle ground in immunology. Unlike their alpha-beta cousins, which recognize peptide fragments presented by major histocompatibility molecules, gamma delta T cells can respond to phosphoantigens, small metabolite-like molecules that accumulate in stressed and transformed cells. This unconventional recognition has made them attractive targets for cancer immunotherapy, and clinical efforts to expand and harness them are underway worldwide. But if gamma delta T cells are to be deployed rationally in the clinic, researchers need to know which checkpoint receptors they carry, when those receptors appear, and what they actually mean for cell function. The new work addresses precisely this gap, and its central message is that checkpoint expression on gamma delta T cells is governed by receptor identity, T-cell lineage, and environmental context all at once.

The experimental design combined laboratory manipulation of living cells with computational mining of published single-cell datasets. The team isolated peripheral blood mononuclear cells from healthy donors and stimulated them in vitro under different conditions, then used flow cytometry to track how checkpoint receptor expression changed over time on both gamma delta and alpha-beta T-cell subsets. In parallel, they reanalyzed previously published single-cell RNA-sequencing data from tumor-infiltrating gamma delta and CD8 T cells, looking for how checkpoint expression was distributed across differentiation states and how it shifted in patients who had received immune checkpoint blockade therapy. This dual approach allowed the researchers to connect what happens in a culture dish with what happens inside human tumors.

The first major finding concerned how different modes of stimulation produce different checkpoint profiles. When the researchers applied polyclonal stimulation, a blunt activation signal that drives many T cells at once, they observed a broad upregulation of checkpoint receptors across the board. But when they expanded V delta 2 T cells, the dominant gamma delta subset in human blood, using phosphoantigen-driven activation, the resulting profile was far more selective. TIM-3 expression rose and remained sustained, while PD-1 and TIGIT showed only transient modulation. In other words, the way a gamma delta T cell is activated leaves a lasting imprint on which brakes it carries, a detail that could matter enormously for clinical protocols that expand these cells ex vivo before infusion into patients.

The second key insight came from mapping checkpoint receptors onto the differentiation journey of T cells. T cells progress through recognizable stages, from naive cells that have never met their antigen, through central memory and effector memory populations, to terminally differentiated effector memory cells. The researchers found that checkpoint distribution was structured along this trajectory, but not in a uniform way. TIGIT was enriched in antigen-experienced subsets, consistent with its association with repeated antigen encounter. LAG-3 and TIM-3, by contrast, were concentrated in naive compartments, an unexpected pattern that challenges the assumption that these receptors simply mark worn-out cells. PD-1 was expressed broadly, appearing across multiple differentiation states rather than clustering at any single stage.

These distribution patterns carry a pointed implication: checkpoint receptor expression alone cannot be used as a proxy for T-cell exhaustion. In alpha-beta T-cell biology, high PD-1 expression is often read as a sign of a dysfunctional, exhausted state that checkpoint blockade can rescue. But the Palermo team’s data show that gamma delta T cells can display checkpoint receptors as a normal feature of activation and differentiation, without any evidence of functional collapse. The authors are careful on this point, noting that because classical exhaustion-associated transcriptional and epigenetic programs were not evaluated in their study, the observed patterns neither establish nor exclude the presence of exhausted gamma delta T-cell subsets. What the data do establish is that checkpoint expression is dynamically shaped by activation history, differentiation state, and environmental context, making single-marker interpretations unreliable.

Functionally, the team tested what happens when the brakes are released. Blocking PD-1 produced donor-dependent trends toward increased proliferation and cytokine production, an effect that was particularly noticeable when the cells were cultured with interleukin-15, a cytokine known to support gamma delta T-cell survival and cytotoxicity. The donor-to-donor variability is itself informative, suggesting that the responsiveness of a patient’s gamma delta T cells to checkpoint blockade may depend on their individual immune baseline. TIM-3 inhibition, meanwhile, showed variable effects across experiments, and combining PD-1 and TIM-3 blockade did not produce a consistent additive response. For a field increasingly interested in combination checkpoint therapies, this absence of synergy in gamma delta T cells is a caution against assuming that strategies validated in alpha-beta biology will transfer cleanly.

The single-cell transcriptomic analysis added a tumor-side perspective. When the researchers examined tumor-infiltrating gamma delta T cells from published datasets, they found heterogeneous checkpoint expression scattered across differentiation states, with no single coherent pattern. CD8 alpha-beta T cells from the same tumors, in comparison, showed a more progressive, stepwise accumulation of checkpoint expression as they differentiated. This lineage-specific architecture suggests that gamma delta T cells inside tumors do not follow the same trajectory of escalating checkpoint burden that characterizes conventional cytotoxic T cells. Intriguingly, the analysis of samples from patients who had undergone immune checkpoint blockade therapy revealed that alternative checkpoint receptors tended to persist or even increase after treatment, hinting at compensatory mechanisms that could blunt therapeutic responses.

The translational stakes of this work are considerable. Gamma delta T cells are being pursued as cellular therapies for cancer, and several approaches involve expanding V delta 2 T cells with aminobisphosphonates such as zoledronic acid, which causes phosphoantigen accumulation in target cells. The finding that phosphoantigen-driven expansion produces a distinctive checkpoint signature, with sustained TIM-3 and only transient PD-1 modulation, gives therapy developers a molecular fingerprint to monitor and potentially manipulate. If the checkpoint profile of an infused gamma delta product determines how long it survives and functions in a patient, then tuning the expansion conditions becomes a rational design parameter rather than an afterthought. Similarly, the donor-dependent response to PD-1 blockade under interleukin-15 stimulation suggests that biomarker-guided patient selection could improve the odds of combination regimens involving gamma delta cells.

Beyond the immediate clinical implications, the study is a reminder that immunology’s most influential paradigms are built on a fraction of the immune system’s diversity. Checkpoint receptors are not a single switch with a single meaning; they are a family of regulatory molecules whose expression and function depend on which T-cell lineage carries them, how that cell was activated, and where it finds itself. For gamma delta T cells, the brakes may be part of the normal operating machinery rather than a sign of breakdown. Disentangling genuine exhaustion from routine checkpoint expression will require integrating receptor measurements with transcriptional and epigenetic profiling, work that the authors flag as the necessary next step. As gamma delta T-cell therapies move closer to the clinic, studies like this one provide the context-dependent framework that careful translation demands, ensuring that the next generation of immunotherapies is designed around how these unconventional cells actually behave.

Subject of Research: Immune checkpoint receptor dynamics in human gamma delta T cells

Article Title: Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells

Article References: Corsale, A. M., Di Simone, M., Cerapio, J. P., Lo Presti, E., Pizzolato, G., Avellone, C., Dieli, C., Marchiafava, S., Di Paola, L., Dieli, F., & Meraviglia, S. (2026). Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09004-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09004-1

Keywords: gamma delta T cells, immune checkpoint receptors, immune checkpoint blockade, T-cell exhaustion, PD-1, TIM-3, TIGIT, LAG-3, single-cell RNA sequencing, cancer immunotherapy, Vdelta2 T cells, flow cytometry

T cell exhaustion is not simply a temporary state of immune fatigue. It represents a complex and relatively stable cellular reprogramming process involving inhibitory receptors, epigenetic remodeling, altered transcription-factor networks, and metabolic dysfunction. When T cells repeatedly encounter antigens from a transplanted organ, they can enter a progressive pathway that begins with functional changes and may culminate in terminal exhaustion. During this process, their capacity for proliferation and effector activity declines, while molecular programs that limit excessive tissue damage become increasingly dominant.

Four immune checkpoint receptors are especially important in this transition: PD-1, CTLA-4, TIM-3, and LAG-3. These molecules transmit inhibitory signals that reduce T cell activation through partly distinct but overlapping pathways. PD-1, for example, can suppress signaling downstream of the T cell receptor by recruiting phosphatases that interfere with activation pathways. CTLA-4 competes with the stimulatory receptor CD28 for binding to costimulatory molecules on antigen-presenting cells. TIM-3 and LAG-3 add further layers of inhibition. Their sustained expression helps maintain exhaustion and can prevent alloreactive T cells from causing extensive damage to transplanted tissue.

The review emphasizes that the exhausted state is reinforced by epigenetic changes that alter how genes are accessed and expressed. DNA methylation, histone modifications, and large-scale chromatin remodeling establish a regulatory landscape distinct from that of effector or memory T cells. These changes can remain after the original antigenic stimulus has been reduced or removed, producing an enduring molecular imprint sometimes described as “epigenetic scarring.” This persistence helps explain why exhausted T cells may not fully recover even when immune conditions change, and why simply blocking inhibitory receptors may not restore their original function.

A network of transcription factors directs the development of exhaustion. TOX is presented as a central regulator, promoting inhibitory receptor expression and activating genes associated with the exhausted phenotype while suppressing programs linked to powerful effector responses. NFAT, NR4A, BATF, IRF4, MYB, and TCF-1 also contribute to the process. TCF-1 is particularly associated with progenitor exhausted cells, a self-renewing population capable of producing more differentiated exhausted cells. This hierarchical organization suggests that exhaustion is not uniform: some exhausted T cells retain proliferative potential and may respond to therapeutic intervention, whereas terminally exhausted cells are more deeply locked into dysfunctional states.

Metabolism provides another critical explanation for declining T cell performance. Activated effector T cells normally increase glucose uptake and rely heavily on glycolysis to generate energy and biosynthetic materials rapidly. Exhausted T cells show impaired glucose utilization and reduced glycolytic capacity. They may become more dependent on fatty acid oxidation, while also developing mitochondrial abnormalities, reduced ATP production, and disturbed amino acid metabolism. Mitochondria can become less efficient and accumulate stress, limiting the energy available for cytokine production and cell division. These metabolic changes are not merely consequences of exhaustion; they can actively reinforce the transcriptional and epigenetic programs that sustain it.

In transplantation, a controlled degree of exhaustion may be beneficial. By reducing the activity of T cells that recognize donor antigens, exhaustion can diminish alloreactive responses, lower the risk of rejection, and contribute to graft acceptance. The effect appears to vary according to the transplanted organ. In kidney transplantation, increased populations of exhausted T cells have been linked in some studies with improved graft function and features of immune tolerance. The liver, naturally exposed to a continuous flow of dietary and microbial antigens, possesses an especially tolerogenic environment that can favor exhaustion. In hematopoietic stem cell transplantation, exhausted donor T cells may reduce graft-versus-host disease, although the same process can weaken graft-versus-leukemia activity, which is essential for eliminating malignant cells.

The immune environment surrounding a graft can actively drive this process. Regulatory T cells, myeloid-derived suppressor cells, M2-polarized macrophages, and natural killer cells may interact with T cells in ways that suppress activation and promote exhaustion. Soluble mediators are also important. TGF-β can reshape transcriptional and epigenetic programs, while IL-10 dampens inflammatory signaling and alters cellular metabolism. Together, these factors can create a local suppressive niche in which exhausted T cells are maintained. Yet excessive suppression carries a cost: antiviral surveillance may decline, allowing latent or newly acquired infections to become more difficult to control, while impaired immune monitoring may increase the risk of post-transplant malignancies.

The authors argue that future transplantation therapies should aim not simply to eliminate exhaustion, but to manage it with greater precision. Strategies could include manipulating checkpoint pathways, modifying metabolic conditions, targeting exhaustion-associated transcription factors, or reshaping the epigenetic state of T cells. The greatest challenge will be separating protective exhaustion, which limits graft injury, from harmful exhaustion, which compromises infection control and tumor surveillance. A better understanding of progenitor and terminally exhausted populations could eventually allow clinicians to preserve tolerance while restoring selected immune functions. The review therefore presents T cell exhaustion as a dynamic therapeutic target—one that may be deliberately induced, restrained, or reversed depending on the clinical needs of each transplant recipient.

Subject of Research: T cell exhaustion in organ transplantation and its molecular mechanisms, clinical effects, and therapeutic modulation.

Article Title: The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies

Web References: https://doi.org/10.1016/j.gendis.2025.101965

References: Yining Wang, You Wu, Yufei Shen, Yujia Chen, Yifan Zhao, Xiandong Zeng, Kang He. “The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies.” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101965.

Image Credits: Genes & Diseases

Keywords: T cell exhaustion, organ transplantation, immune tolerance, graft rejection, PD-1, CTLA-4, TIM-3, LAG-3, epigenetics, TOX, TCF-1, metabolism, transplant immunology

Emerging evidence highlights that checkpoint pathways are intricately involved in maintaining systemic immune homeostasis. The occurrence of multisystem immune-related adverse events following ICI treatment suggests that these molecules influence immune balance throughout the body, not merely within tumors. Consequently, immune checkpoints are now seen as key integrators linking localized inflammatory microenvironments with systemic immune responses.

This paradigm shift is reinforced by observations of abnormal immune checkpoint activity in a spectrum of conditions, including infectious diseases, autoimmune disorders, metabolic and cardiovascular inflammation, and tissue injury. These findings underscore that ICs, such as PD-1/PD-L1, CTLA-4, TIGIT, TIM-3, and LAG-3, operate within complex inflammatory and metabolic networks, modulating immune exhaustion, tissue tolerance, and chronic inflammation beyond cancer contexts.

Crucially, a variety of inflammatory cues—including cytokines, metabolites, oxidative stress signals, and tissue-derived factors—can regulate checkpoint expression and function. The dynamic crosstalk between these signals shapes immune cell phenotypes and influences whether immune responses are amplified, subdued, or persist chronically. Thus, immune checkpoints serve as central hubs orchestrating the balance of immune activation and tolerance in diverse physiological and pathological settings.

By integrating checkpoint signaling with broader cytokine networks and metabolic reprogramming, researchers aim to develop precision immunotherapies that fine-tune immune modulation. Such strategies seek to maximize therapeutic efficacy against tumors while minimizing adverse events related to systemic immune dysregulation. This holistic approach represents a promising advance toward personalized medicine in immunotherapy.

The authors of the recent review published in TransMed call for an expanded conceptual framework that recognizes immune checkpoints as pivotal moderators in both local and systemic immune regulation. Understanding the molecular underpinnings of checkpoint pathways and their interactions with inflammatory signals may unlock novel avenues for treating not only cancer but also a wide array of inflammatory and autoimmune diseases.

This evolving perspective propels the field beyond the traditional tumor-centric model, inviting innovative research into how checkpoint modulation can balance immune protection with tissue homeostasis. As immune checkpoint biology continues to unfold, it holds the potential to transform therapeutic approaches across multiple disciplines, heralding new horizons in immunity and inflammation regulation.

Contact with the corresponding author Wangzhiqi Zhang emphasizes the importance of linking checkpoint biology to immune safety, aiming to harness these pathways thoughtfully in clinical applications. This insight may guide the future design of checkpoint-targeted therapies with improved precision and reduced systemic toxicity.

Subject of Research: Not applicable
Article Title: Unlocking new horizons in immunity: The roles and mechanisms of immune checkpoints in inflammation regulation
References: 10.1016/j.tmed.2026.100021
Image Credits: Lizhou Song, Yan Liao, Yue Shu, Wenwen Shao, Chenglong Zhu, Haoling Zhang, Yadong Guo, and Wangzheqi Zhang